Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:AUTL NASDAQ:GLUE NYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$27.99+0.7%$29.62$22.24▼$46.00$1.65B0.581.33 million shs794,283 shsAUTLAutolus Therapeutics$1.58+0.6%$1.49$1.18▼$2.70$417.85M1.931.32 million shs1.29 million shsGLUEMonte Rosa Therapeutics$20.26+4.5%$17.76$3.51▼$25.77$1.64B1.62811,333 shs1.04 million shsNUVBNuvation Bio$4.77-0.5%$4.64$1.57▼$9.75$1.66B1.514.20 million shs2.78 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.72%-0.60%-14.98%+3.17%+2.45%AUTLAutolus Therapeutics+0.64%+7.48%+6.04%+10.49%+19.70%GLUEMonte Rosa Therapeutics+4.49%+7.77%+15.90%+3.53%+392.94%NUVBNuvation Bio-0.19%+6.50%+4.20%-16.82%+128.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$27.99+0.7%$29.62$22.24▼$46.00$1.65B0.581.33 million shs794,283 shsAUTLAutolus Therapeutics$1.58+0.6%$1.49$1.18▼$2.70$417.85M1.931.32 million shs1.29 million shsGLUEMonte Rosa Therapeutics$20.26+4.5%$17.76$3.51▼$25.77$1.64B1.62811,333 shs1.04 million shsNUVBNuvation Bio$4.77-0.5%$4.64$1.57▼$9.75$1.66B1.514.20 million shs2.78 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.72%-0.60%-14.98%+3.17%+2.45%AUTLAutolus Therapeutics+0.64%+7.48%+6.04%+10.49%+19.70%GLUEMonte Rosa Therapeutics+4.49%+7.77%+15.90%+3.53%+392.94%NUVBNuvation Bio-0.19%+6.50%+4.20%-16.82%+128.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.5648.47% UpsideAUTLAutolus Therapeutics 2.89Moderate Buy$8.50437.97% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$32.5060.41% UpsideNUVBNuvation Bio 2.70Moderate Buy$12.50162.27% UpsideCurrent Analyst Ratings BreakdownLatest AUTL, NUVB, AGIO, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026GLUEMonte Rosa Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $31.005/5/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.005/5/2026NUVBNuvation Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.005/5/2026NUVBNuvation Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.004/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026NUVBNuvation Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.004/20/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $50.004/20/2026AUTLAutolus Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/16/2026NUVBNuvation Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M30.81N/AN/A$20.46 per share1.37AUTLAutolus Therapeutics$75.39M5.58N/AN/A$0.67 per share2.36GLUEMonte Rosa Therapeutics$123.67M13.84N/AN/A$3.58 per share5.66NUVBNuvation Bio$143.05M11.58N/AN/A$0.88 per share5.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)AUTLAutolus Therapeutics-$287.53M-$1.08N/AN/AN/A-381.40%-99.05%-42.31%5/14/2026 (Estimated)GLUEMonte Rosa Therapeutics-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%N/ANUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%N/ALatest AUTL, NUVB, AGIO, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026AUTLAutolus Therapeutics-$0.29N/AN/AN/A$26.27 millionN/A5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 million5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 million3/17/2026Q4 2025GLUEMonte Rosa Therapeutics-$0.45-$0.55-$0.10-$0.55$17.09 million$2.78 million3/2/2026Q4 2025NUVBNuvation Bio-$0.11-$0.11N/A-$0.11$36.82 million$41.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59AUTLAutolus TherapeuticsN/A5.945.48GLUEMonte Rosa TherapeuticsN/A9.549.54NUVBNuvation Bio0.157.447.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AAUTLAutolus Therapeutics72.83%GLUEMonte Rosa Therapeutics79.96%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%AUTLAutolus Therapeutics25.70%GLUEMonte Rosa Therapeutics6.40%NUVBNuvation Bio30.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableGLUEMonte Rosa Therapeutics9084.48 million79.07 millionOptionableNUVBNuvation Bio60347.60 million243.36 millionOptionableAUTL, NUVB, AGIO, and GLUE HeadlinesRecent News About These CompaniesNuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesMay 8, 2026 | finance.yahoo.comNuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 8, 2026 | americanbankingnews.comNuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small ...May 8, 2026 | uk.finance.yahoo.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)May 7, 2026 | prnewswire.comQ2 EPS Estimates for Nuvation Bio Lowered by HC WainwrightMay 7, 2026 | marketbeat.comWedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB)May 7, 2026 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Earns "Buy" Rating from HC WainwrightMay 7, 2026 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Earns Outperform Rating from Royal Bank Of CanadaMay 7, 2026 | americanbankingnews.comNuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung CancerMay 6, 2026 | prnewswire.comNuvation Bio to Participate in Upcoming Investor ConferencesMay 5, 2026 | prnewswire.comNuvation Bio's (NUVB) "Outperform" Rating Reaffirmed at Royal Bank Of CanadaMay 5, 2026 | marketbeat.comNuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from WedbushMay 5, 2026 | marketbeat.comNuvation Bio (NYSE:NUVB) Earns Buy Rating from HC WainwrightMay 5, 2026 | marketbeat.comNuvation Bio Inc. (NUVB) Q1 2026 Earnings Call TranscriptMay 4, 2026 | seekingalpha.comNuvation Bio Q1 Earnings Call HighlightsMay 4, 2026 | marketbeat.comNuvation Bio Inc. (NUVB) Lags Q1 Earnings EstimatesMay 4, 2026 | zacks.comNuvation Bio (NYSE:NUVB) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPSMay 4, 2026 | marketbeat.comNuvation Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 4, 2026 | prnewswire.comNuvation Bio Inc. (NYSE:NUVB) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 3, 2026 | marketbeat.comNuvation Bio Inc (NUVB) Q1 2026 Earnings Report Preview: What To ExpectMay 1, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)April 30, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUTL, NUVB, AGIO, and GLUE Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$27.99 +0.20 (+0.72%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$27.25 -0.74 (-2.64%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Autolus Therapeutics NASDAQ:AUTL$1.58 +0.01 (+0.64%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$1.61 +0.03 (+1.84%) As of 07:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Monte Rosa Therapeutics NASDAQ:GLUE$20.26 +0.87 (+4.49%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$20.15 -0.11 (-0.53%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Nuvation Bio NYSE:NUVB$4.77 -0.02 (-0.50%) Closing price 05/11/2026 03:59 PM EasternExtended Trading$4.83 +0.07 (+1.36%) As of 06:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
